Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients

Antiviral Therapy

Volumn 13, Issue 5, 2008, Pages 739-742

  Pea, Federico ^a   Tavio, Marcello ^a   Pavan, Federica ^a   Londero, Angela ^a   Bresadola, Vittorio ^a   Adani, Gian Luigi ^a   Furlanut, Mario ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; TACROLIMUS; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SURGICAL PATIENT;

ADULT; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NELFINAVIR; PHOSPHORIC ACID ESTERS; SULFONAMIDES; TACROLIMUS;

EID: 49949110361     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Honda M, Oka S. Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Int J Hematol 2006; 84:18-22.
2. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-1420.
3. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-247.
4. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816-2820.
5. Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006; 38:1138-1140.
6. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9:954-960.
7. Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8:841-845.
8. Schvarcz R, Rudbeck G, Soderdahl G, Stable L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69:2194-2195.
9. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46:941-952.
10. Viracept contaminated in Europe. AIDS patient care and STDs 2007; 21:521.
11. Ross L, Vavro C, Wine B, Liao Q. Fosamprenavir clinical study meta-analysis in ART-naive subjects: rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin Trials 2006; 7:334-338.
12. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45:137-168.
13. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22:328-335.
14. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007; 3:583-598.
15. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98:79-85.
16. Ernest CS, 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312:583-591.
17. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156:319-329.
18. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12:927-941.
19. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73:1573-1581.